Catalent amps up plans to manufacture J&J's Covid-19 vaccine, adding vial filling line in Italy
A little more than a year after Catalent CEO John Chiminski acquired Bristol Myers Squibb’s manufacturing facility in Anagni, Italy, the big CDMO is using it to amp up supplies of J&J’s Covid-19 vaccine.
On Wednesday the pharma giant announced an expanded deal to lay on added manufacturing capacity involving vial-filling, inspection, labeling, and packaging services. Catalent plans to scale up a new, high speed vial filling line to increase production for J&J’s one-shot vaccine, which recently won a major OK in the US. The sprawling plant encompasses 300,000 square feet of space.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,300+ biopharma pros reading Endpoints daily — and it's free.